[1]刘春梦,丁珊,刘雪英,等.Ang/Tie信号轴在新生血管性年龄相关性黄斑变性发病及治疗中的作用[J].眼科新进展,2022,42(6):485-490.[doi:10.13389/j.cnki.rao.2022.0099]
　LIU Chunmeng,DING Shan,LIU Xueying,et al.Role of Ang/Tie signaling axis in the pathogenesis and treatment of neovascular age-related macular degeneration[J].Recent Advances in Ophthalmology,2022,42(6):485-490.[doi:10.13389/j.cnki.rao.2022.0099]
点击复制

Ang/Tie信号轴在新生血管性年龄相关性黄斑变性发病及治疗中的作用/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
42卷
期数:
2022年6期
页码:
485-490
栏目:
文献综述
出版日期:
2022-06-05

文章信息/Info

Title:
Role of Ang/Tie signaling axis in the pathogenesis and treatment of neovascular age-related macular degeneration
作者:
刘春梦; 丁珊; 刘雪英; 周静; 黄鹏; 周雨欣; 张富文
610075　四川省成都市，成都中医药大学（刘春梦，丁珊，刘雪英，周静，黄鹏，周雨欣，张富文）；610084　四川省成都市，成都中医药大学附属银海眼科医院（张富文）
Author(s):
LIU Chunmeng1; DING Shan1; LIU Xueying1; ZHOU Jing1; HUANG Peng1; ZHOU Yuxin1; ZHANG Fuwen1; 2
1.Chengdu University of Traditional Chinese Medicine,Chengdu 610075,Sichuan Province，China
2.Ineye Hospital of Chengdu University of Traditional Chinese Medicine,Chengdu 610084,Sichuan Province,China
关键词:
血管生成素; 酪氨酸激酶受体; 血管生成; 新生血管性年龄相关性黄斑变性
Keywords:
angiopoietin;  tyrosine kinase receptor;  angiogenesis;  neovascular age-related macular degeneration
分类号:
R773.4
DOI:
10.13389/j.cnki.rao.2022.0099
文献标志码:
A
摘要:
血管生成素(Ang)/酪氨酸激酶受体Tie信号轴（Ang/Tie信号轴）在调节血管稳定性、血管生成以及炎症等方面发挥着重要作用。Ang1支持静止和成熟的血管表型，而Ang2常与异常的血管结构形成、血管渗漏和炎症有关。新生血管性年龄相关性黄斑变性(nAMD)是一种能导致患者出现严重视力损害的疾病，其病理特征是脉络膜新生血管的形成及炎症反应。Ang/Tie信号轴是治疗nAMD的新靶点。靶向Ang/Tie信号轴的治疗方法可促进血管稳定，抑制渗漏及炎症，与抗血管生成药物联合治疗时可产生协同作用。本文对Ang/Tie信号轴在nAMD发病及治疗中的作用进行综述，以期为nAMD的治疗提供新思路。
Abstract:
The angiopoietin (Ang)/tyrosine kinase receptor Tie signaling axis (Ang/Tie signaling axis) plays an important role in regulating vascular stability, angiogenesis and inflammation. Ang1 supports quiescent and mature vascular phenotype, while Ang2 is often associated with the formation of abnormal vascular structure, vascular leakage and inflammation. Neovascular age-related macular degeneration (nAMD) is a disease that can cause severe visual impairment in patients, which is pathologically characterized by the choroidal neovascularization and inflammatory reaction. Ang/Tie signaling axis is a new target for the treatment of nAMD. The therapy targeting Ang/Tie signaling axis can promote vascular stability, inhibit leakage and inflammation, and generate a synergistic effect with anti-angiogenic drugs. This article reviews the role of Ang/Tie signaling axis in the pathogenesis and treatment of nAMD, in order to provide new ideas for the treatment of nAMD.

参考文献/References:

［1］　CHEN Z J,MA L,BRELEN M E,CHEN H,TSUJIKAWA M,LAI T Y,et al.Identification of TIE2 as a susceptibility gene for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy［J］.Br J Ophthalmol,2021,105(7):1035-1040.
［2］　WONG W L,SU X,LI X,CHEUNG C M,KLEIN R,CHENG C Y,et al.Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040:a systematic review and meta-analysis［J］.Lancet Glob Health,2014,2(2):e106-e116.
［3］　YANG S,ZHAO J,SUN X.Resistance to anti-VEGF therapy in neovascular age-related macular degeneration:a comprehensive review［J］.Drug Des Devel Ther,2016,10:1857-1867.
［4］　ROSENFELD P J,BROWN D M,HEIER J S,BOYER D S,KAISER P K,CHUNG C Y,et al.Ranibizumab for neovascular age-related macular degeneration［J］.N Engl J Med,2006,355(14):1419-1431.
［5］　Group Research CATT,MARTIN D F,MAGUIRE M G,YING G S,GRUNWALD J E,FINE S L,et al.Ranibizumab and bevacizumab for neovascular age-related macular degeneration［J］.N Engl J Med,2011,364(20):1897-1908.
［6］　HEIER J S,BROWN D M,CHONG V,KOROBELNIK J F,KAISER P K,NGUYEN Q D,et al.Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration［J］.Ophthalmology,2012,119(12):2537-2548.
［7］　OTSUJI T,NAGAI Y,SHO K,TSUMURA A,KOIKE N,TSUDA M,et al.Initial non-responders to ranibizumab in the treatment of age-related macular degeneration (AMD)［J］.Clin Ophthalmol,2013,7:1487-1490.
［8］　SUZUKI M,NAGAI N,IZUMI-NAGAI K,SHINODA H,KOTO T,UCHIDA A,et al.Predictive factors for non-response to intravitreal ranibizumab treatment in age-related macular degeneration［J］.Br J Ophthalmol,2014,98(9):1186-1191.
［9］　KIM J,PARK J R,CHOI J,PARK I,HWANG Y,BAE H,et al.Tie2 activation promotes choriocapillary regeneration for alleviating neovascular age-related macular degeneration［J］.Sci Adv,2019,5(2):eaau6732.
［10］　AUGUSTIN H G,KOH G Y,THURSTON G,ALITALO K.Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system［J］.Nat Rev Mol Cell Biol,2009,10(3):165-177.
［11］　KORHONEN E A,LAMPINEN A,GIRI H,ANISIMOV A,KIM M,ALLEN B,et al.Tie1 controls angiopoietin function in vascular remodeling and inflammation［J］.J Clin Invest,2016,126(9):3495-3510.
［12］　HEIER J S,SINGH R P,WYKOFF C C,CSAKY K G,LAI T,LOEWENSTEIN A,et al.The angiopoietin/tie pathway in retinal vascular diseases:a review［J］.Retina,2021,41(1):1-19.
［13］　LEE J,PARK D Y,PARK DYFAU-PARK D Y,PARK I,CHANG W,NAKAOKA Y,et al.Angiopoietin-1 suppresses choroidal neovascularization and vascular leakage［J］.Invest Ophthalmol Vis Sci,2014,55(4):2191-2199.
［14］　NAMBU H,NAMBU R,OSHIMA Y,HACKETT S F,OKOYE G,WIEGAND S,et al.Angiopoietin 1 inhibits ocular neovascularization and breakdown of the blood-retinal barrier［J］.Gene Ther,2004,11(10):865-873.
［15］　ZIEGLER T,HORSTKOTTE J,SCHWAB C,PFETSCH V,WEINMANN K,DIETZEL S,et al.Angiopoietin 2 mediates microvascular and hemodynamic alterations in sepsis［J］.J Clin Invest,2013,123(8):3436-3445.
［16］　FELCHT M,LUCK R,SCHERING A,SEIDEL P,SRIVASTAVA K,HU J H,et al.Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signaling［J］.J Clin Invest,2012,122(6):1991-2005.
［17］　HAKANPAA L,SIPILA T,LEPPANEN V M,GAUTAM P,NURMI H,JACQUEMET G,et al.Endothelial destabilization by angiopoietin-2 via integrin β1 activation［J］.Nat Commun,2015,6:5962.
［18］　VALENZUELA D M,GRIFFITHS J A,ROJAS J,ALDRICH T H,JONES P F,ZHOU H,et al.Angiopoietins 3 and 4:diverging gene counterparts in mice and humans［J］.Proc Natl Acad Sci USA,1999,96(5):1904-1909.
［19］　ELAMAA H,KIHLSTRM M,KAPIAINEN E,KAAKINEN M,MIINALAINEN I,RAGAUSKAS S,et al.Angiopoietin-4-dependent venous maturation and fluid drainage in the peripheral retina［J］.Elife,2018,7:e37776.
［20］　FUKUHARA S,SAKO K,MINAMI T,NODA K,KIM H Z,KODAMA T,et al.Differential function of Tie2 at cell-cell contacts and cell-substratum contacts regulated by angiopoietin-1［J］.Nat Cell Biol,2008,10(5):513-526.
［21］　SAHARINEN P,EKLUND L,MIETTINEN J,WIRKKALA R,ANISIMOV A,WINDERLICH M,et al.Angiopoietins assemble distinct Tie2 signalling complexes in endothelial cell-cell and cell-matrix contacts［J］.Nat Cell Biol,2008,10(5):527-537.
［22］　KIM I,KIM H G,SO J N,KIM J H,KWAK H J,KOH G Y.Angiopoietin-1 regulates endothelial cell survival through the phosphatidylinositol 3’-Kinase/Akt signal transduction pathway［J］.Circ Res,2000,86(1):24-29.
［23］　DALY C,WONG V,BUROVA E,WEI Y,ZABSKI S,GRIFFITHS J,et al.Angiopoietin-1 modulates endothelial cell function and gene expression via the transcription factor FKHR (FOXO1)［J］.Genes Dev.2004,18(9):1060-1071.
［24］　KOH G Y.Orchestral actions of angiopoietin-1 in vascular regeneration［J］.Trends Mol Med,2013,19(1):31-39.
［25］　FRYE M,DIERKES M,KPPERS V,VOCKEL M,TOMM J,ZEUSCHNER D,et al.Interfering with VE-PTP stabilizes endothelial junctions in vivo via Tie-2 in the absence of VE-cadherin［J］.J Exp Med,2015,212(13):2267-2287.
［26］　SHEN J,FRYE M,LEE B L,REINARDY J L,MCCLUNG J M,DING K,et al.Targeting VE-PTP activates TIE2 and stabilizes the ocular vasculature［J］.J Clin Invest,2014,124(10):4564-4576.
［27］　钱程,郑维维,邹伟,杨春媚,张珊,吴媛媛,等.Ang/Tie轴对肿瘤血管生成和转移作用的研究进展［J］.药学学报,2020,55(10):2291-2297.
QIAN C,ZHENG W W,ZOU W,YANG C M,ZHANG S,WU Y Y,et al.Research progress on the role of Ang/Tie axis in angiogenesis and metastasis［J］.Acta Pharm Sin,2020,55(10):2291-2297.
［28］　LEE J,KIM K E,CHOI D K,JY J,JUNG J J,KIYONARI H,et al.Angiopoietin-1 guides directional angiogenesis through integrin αvβ5 signaling for recovery of ischemic retinopathy［J］.Sci Transl Med,2013,5(203):203ra127.
［29］　PIETIL R,NTYNKI M,TAMMELA T,KANGAS J,PULKKI K H,LIMAYE N,et al.Ligand oligomerization state controls Tie2 receptor trafficking and angiopoietin-2-specific responses［J］.J Cell Sci,2012,125(Pt 9):2212-2223.
［30］　PARK S W,YUN J H,KIM J H,KIM K W,CHO C H,KIM J H.Angiopoietin 2 induces pericyte apoptosis via α3β1 integrin signaling in diabetic retinopathy［J］.Diabetes,2014,63(9):3057-3068.
［31］　WINDERLICH M,KELLER L,CAGNA G,BROERMANN A,KAMENYEVA O,KIEFER F,et al.VE-PTP controls blood vessel development by balancing Tie-2 activity［J］.J Cell Biol,2009,185(4):657-671.
［32］　CARRA S,FOGLIA E,CERMENATI S,BRESCIANI E,GIAMPIETRO C,LORA L C,et al.Ve-ptp modulates vascular integrity by promoting adherens junction maturation［J］.PLoS One,2012,7(12):e51245.
［33］　THURSTON G,DALY C.The complex role of angiopoietin-2 in the angiopoietin-tie signaling pathway［J］.Cold Spring Harb Perspect Med,2012,2(9):a006550.
［34］　BIEL N M,SIEMANN D W.Targeting the angiopoietin-2/Tie-2 axis in conjunction with VEGF signal interference［J］.Cancer Lett,2016,380(2):525-533.
［35］　NAMBU H,UMEDA N,KACHI S,OSHIMA Y,AKIYAMA H,NAMBU R,et al.Angiopoietin 1 prevents retinal detachment in an aggressive model of proliferative retinopathy,but has no effect on established neovascularization［J］.J Cell Physiol,2005,204(1):227-235.
［36］　GAVARD J,GUTKIND J S.VEGF controls endothelial-cell permeability by promoting the beta-arrestin-dependent endocytosis of VE-cadherin［J］.Nat Cell Biol,2006,8(11):1223-1234.
［37］　BROERMANN A,WINDERLICH M,BLOCK H,FRYE M,ROSSAINT J,ZARBOCK A,et al.Dissociation of VE-PTP from VE-cadherin is required for leukocyte extravasation and for VEGF-induced vascular permeability in vivo［J］.J Exp Med,2011,208(12):2393-2401.
［38］　GAVARD J,PATEL V,GUTKIND J S.Angiopoietin-1 prevents VEGF-induced endothelial permeability by sequestering Src through mDia［J］.Dev Cell,2008,14(1):25-36.
［39］　PETERS S,CREE I A,ALEXANDER R,TUROWSKI P,OCKRIM Z,PATEL J,et al.Angiopoietin modulation of vascular endothelial growth factor:effects on retinal endothelial cell permeability［J］.Cytokine,2007,40(2):144-150.
［40］　NGUYEN Q D,HEIER J S,DO D V,MIRANDO A C,PANDEY N B,SHENG H,et al.The tie2 signaling pathway in retinal vascular diseases:a novel therapeutic target in the eye［J］.Int J Retina Vitreous,2020,6:48.
［41］　NGUYEN Q D,DAS A,DO D V,DUGEL P,GOMES A,HOLZ F G,et al.Brolucizumab:evolution through preclinical and clinical studies and the implications for the management of neovascular age-related macular degeneration［J］.Ophthalmology,2020,127(7):963-976.
［42］　MA L,BRELEN M E,TSUJIKAWA M,CHEN H,CHU W K,LAI T Y,et al.Identification of ANGPT2 as a new gene for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy in the Chinese and Japanese populations［J］.Invest Ophthalmol Vis Sci,2017,58(2):1076-1083.
［43］　NG D S,YIP Y W,BAKTHAVATSALAM M,CHEN L J,NG T K,LAI T Y,et al.Elevated angiopoietin 2 in aqueous of patients with neovascular age related macular degeneration correlates with disease severity at presentation［J］.Sci Rep,2017,7:45081.
［44］　OTANI A,TAKAGI H,OH H,KOYAMA S,MATSUMURA M,HONDA Y.Expressions of angiopoietins and Tie2 in human choroidal neovascular membranes［J］.Invest Ophthalmol Vis Sci,1999,40(9):1912-1920.
［45］　HUBER M,WACHTLIN J.Vitreous levels of proteins implicated in angiogenesis are modulated in patients with retinal or choroidal neovascularization［J］.Ophthalmologica,2012,228(3):188-193.
［46］　LAMBERT N G,ZHANG X,RAI R R,UEHARA H,CHOI S,CARROLL L S,et al.Subretinal AAV2.COMP-Ang1 suppresses choroidal neovascularization and vascular endothelial growth factor in a murine model of age-related macular degeneration ［J］.Exp Eye Res,2016,145:248-257.
［47］　REGULA J T,LUNDH P,FOXTON R,BARATHI V A,CHEUNG C M,BO S B,et al. Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases［J］.EMBO Mol Med.2016,8(11):1265-1288.
［48］　JOUSSEN A M,POULAKI V,TSUJIKAWA A,QIN W,QAUM T,XU Q,et al.Suppression of diabetic retinopathy with angiopoietin-1［J］.Am J Pathol,2002,160(5):1683-1693.
［49］　FIEDLER U,REISS Y,SCHARPFENECKER M,GRUNOW V,KOIDL S,THURSTON G,et al.Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation［J］.Nat Med,2006,12(2):235-239.
［50］　FOXTON R H,UHLES S,GRNER S,REVELANT F,ULLMER C.Efficacy of simultaneous VEGF-A/ANG-2 neutralization in suppressing spontaneous choroidal neovascularization［J］.EMBO Mol Med,2019,11(5):e10204.
［51］　FRIEDLANDER M.Fibrosis and diseases of the eye［J］.J Clin Invest,2007,117(3):576-586.
［52］　VISCONTI R P,RICHARDSON C D,SATO T N.Orchestration of angiogenesis and arteriovenous contribution by angiopoietins and vascular endothelial growth factor (VEGF)［J］.Proc Natl Acad Sci USA,2002,99(12):8219-8224.
［53］　KLAASSEN I,DE VRIES E W,VOGELS I,VAN KAMPEN A,BOSSCHA M,STEEL D,et al.Identification of proteins associated with clinical and pathological features of proliferative diabetic retinopathy in vitreous and fibrovascular membranes［J］.PLoS One,2017,12(11):e0187304.
［54］　KHANANI A M,PATEL S S,FERRONE P J,OSBORNE A,SAHNI J,GRZESCHIK S,et al.Efficacy of every four monthly and quarterly dosing of faricimab vs ranibizumab in neovascular Age-Related macular degeneration:the STAIRWAY phase 2 randomized clinical trial［J］.JAMA Ophthalmol,2020,138(9):964-972.
［55］　SAHNI J,PATEL S S,DUGEL P,KHANANI A M,JHAVERI C D,WYKOFF C C,et al.Simultaneous inhibition of angiopoietin-2 and vascular endothelial growth factor-A with faricimab in diabetic macular edema:BOULEVARD phase 2 randomized trial［J］.Ophthalmology,2019,126(8):1155-1170.
［56］　CAMPOCHIARO P A,KHANANI A,SINGER M,PATEL S,BOYER D,DUGEL P,et al.Enhanced benefit in diabetic macular edema from AKB-9778 tie2 activation combined with vascular endothelial growth factor suppression［J］.Ophthalmology,2016,123(8):1722-1730.
［57］　BROWN D M,BOYER D S,CSAKY K,VITTI R,PERLEE L,CHU K W,et al.Intravitreal Nesvacumab (anti-angiopoietin 2) plus aflibercept in diabetic macular edema:the phase 2 RUBY randomized trial［J］.Retina,2022,Epub ahead of print.
［58］　HEIER J S,KHANANI A M,QUEZADA RUIZ C,BASU K,FERRONE P J,BRITTAIN C,et al.Efficacy,durability,and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE):two randomised,double-masked,phase 3,non-inferiority trials［J］.Lancet,2022,399(10326):729-740.
［59］　MIRANDO A C,SHEN J,SILVA R,CHU Z,SASS N C,LORENC V E,et al.A collagen IV-derived peptide disrupts α5β1 integrin and potentiates Ang2/Tie2 signaling［J］.JCI Insight,2019,4(4):122043.
［60］　CHAKRAVARTHY U,BAILEY C,BROWN D,CAMPOCHIARO P,CHITTUM M,CSAKY K,et al.Phase I trial of anti-vascular endothelial growth factor/anti-angiopoietin 2 bispecific antibody RG7716 for neovascular age-related macular degeneration［J］.Ophthalmol Retina,2017,1(6):474-485.
［61］　SILVA R L E,KANAN Y,MIRANDO A C,KIM J,SHMUELI R B,LORENC V E,et al.Tyrosine kinase blocking collagen IV-derived peptide suppresses ocular neovascularization and vascular leakage［J］.Sci Transl Med,2017,9(373):eaai8030.

相似文献/References:

[1]王燕云,张栋彦,耿园园,等.血管生成素对脂多糖诱导的急性葡萄膜炎小鼠的抗炎作用[J].眼科新进展,2020,40(10):933.[doi:10.13389/j.cnki.rao.2020.0210]
　WANG Yanyun,ZHANG Dongyan,GENG Yuanyuan,et al.Anti-inflammatory effect of angiopoietin in lipopolysaccharide induced acute uveitis in mice[J].Recent Advances in Ophthalmology,2020,40(6):933.[doi:10.13389/j.cnki.rao.2020.0210]

备注/Memo

备注/Memo:
国家自然科学基金资助（编号：82004428）；成都中医药大学“杏林学者”学科人才项目（编号：YXRC2018013）
更新日期/Last Update: 2022-06-05